Opportunity Information: Apply for PA 09 005
Apply for PA 09 005
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.399 Cancer Control.
- This funding opportunity was created on Oct 6, 2008 and posted on Oct 6, 2008.
- Applicants must submit their applications by Jan 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Private institutions of higher education Small businesses County governments Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Regional Organizations U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery (R21) is a National Cancer Institute (NCI) funding opportunity that supports health services research focused on how newer cellular, molecular, genetic, and genomic (CMG) technologies are actually being used in real-world cancer care. The central idea is not to develop the lab science behind these tools, but to study what happens when they move into clinical practice: how they change care decisions, how systems adapt (or fail to), what they cost, who gets access, and whether they measurably improve patient outcomes. The announcement is designed for exploratory, early-stage projects that can generate actionable evidence and set up larger, more definitive studies later.
The research scope is broad but clearly oriented toward practical delivery questions. Applicants are encouraged to evaluate CMG technologies in relation to quality of care, meaning whether use of a test or assay improves appropriateness of treatment, adherence to guidelines, timeliness, safety, or patient-centered care. Another major emphasis is on organizational barriers and enabling factors that influence uptake, such as clinical workflow, staffing and expertise, infrastructure for specimen handling and interpretation, reimbursement and billing practices, leadership support, and the way test results are communicated and acted upon across teams. The FOA also highlights economic evaluation, including direct and indirect costs, budget impact, and cost-effectiveness, reflecting the reality that many CMG tools can be expensive and require supporting services beyond the test itself.
Equity is a specific and prominent priority. The FOA calls for studies of disparities in both access and effectiveness, which can include differences by race and ethnicity, income, geography, insurance status, age, disability, language, and rural versus urban settings. This can involve documenting gaps in availability of CMG testing, differences in referral patterns, unequal access to specialist interpretation, or unequal ability to receive targeted therapies once a biomarker is identified. Importantly, it also invites work on whether the performance of these technologies differs across populations in routine practice, which can happen if initial evidence was generated in narrow or non-representative patient samples.
The announcement also encourages monitoring how CMG technologies diffuse over time and across settings. That includes cross-sectional patterns of care and time trends, such as how quickly a new genomic test is adopted, which kinds of hospitals or practices adopt first, whether adoption spreads to community settings, and whether usage aligns with evidence and guidelines. Another key area is understanding how these technologies affect existing standards of care. For example, a new biomarker test may shift who gets chemotherapy, alter surgical decision-making, change surveillance intensity, or influence eligibility for clinical trials. The FOA is interested in downstream effects like overuse, underuse, and unintended consequences, not just intended benefits.
A defining feature of this opportunity is that it explicitly welcomes studies of both commercially available CMG clinical tools that are already in use and experimental tools that are in later-stage development or moving through regulatory review. In practice, this means applicants can examine technologies that clinicians are already ordering, as well as tools that are close to entering routine care where early evidence about implementation and delivery impact could shape how they are rolled out. The FOA also pushes for interdisciplinary collaboration, especially partnerships between health services researchers and clinical and/or translational scientists, to ensure studies are grounded in clinical realities while using strong methods from health economics, implementation science, outcomes research, epidemiology, and policy analysis.
This funding announcement uses the NIH R21 exploratory/developmental grant mechanism. R21s are typically used for innovative, higher-risk, early-phase projects where the goal is to explore feasibility, develop preliminary data, pilot a new approach, or test a promising concept that can lead to a larger R01 later. The FOA notes it is run in parallel with a companion announcement of the same scientific scope that uses the R01 mechanism (PA 09 004), which is relevant for applicants deciding whether their project is best suited to a smaller exploratory award versus a full-scale research project.
From an administrative and eligibility standpoint, this is a discretionary grant opportunity administered by the National Institutes of Health, with a CFDA listing of 93.399 (Cancer Control). It does not require cost sharing or matching. The listed award ceiling is $200,000, consistent with the small, exploratory nature of an R21. The opportunity was posted October 6, 2008, and the final closing date shown is January 7, 2012 (it is archived as of February 7, 2012). The anticipated number of awards is not specified and depends on available funds and the number of meritorious applications received.
Eligibility is broad and includes public and private institutions of higher education, nonprofits with and without 501(c)(3) status (other than institutions of higher education), for-profit organizations (including small businesses and other for-profits), and state and county governments. The eligibility section also indicates additional eligible applicants can include certain federal agencies, regional organizations, and U.S. territories or possessions. The overall intent is to attract a wide range of applicants capable of studying how CMG technologies affect cancer care delivery in diverse real-world environments, from academic medical centers to community practices and health systems, as well as policy and payer contexts.
FAQs: Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery (R21)
1) What is this funding opportunity about?
This National Cancer Institute (NCI) opportunity supports health services research on how emerging cellular, molecular, genetic, and genomic (CMG) technologies are used in real-world cancer care and what effects they have on care delivery, costs, access, and patient outcomes.
2) Is this grant meant to fund laboratory development of new CMG technologies?
No. The focus is not on developing the underlying laboratory science. The emphasis is on studying what happens when CMG technologies move into clinical practice, including how care decisions change, how health systems adapt, and whether outcomes improve.
3) What grant mechanism is used?
The opportunity uses the NIH R21 exploratory/developmental grant mechanism, which is designed for early-stage, innovative, and potentially higher-risk projects that can generate actionable evidence and inform larger studies later.
4) What kinds of research questions fit the scope?
Projects should focus on practical cancer care delivery questions related to CMG technologies, such as how tests are adopted and used, how results influence treatment choices, what organizational factors help or hinder use, what the economic impact is, and whether use is equitable across populations and settings.
5) What does the FOA mean by studying “real-world” use of CMG technologies?
It refers to evaluating how CMG tools are actually used in routine clinical settings (not just under controlled research conditions), including workflow realities, staffing and infrastructure constraints, reimbursement dynamics, and how test results are communicated and acted on across clinical teams.
6) How does the FOA define “quality of care” in this context?
The FOA encourages evaluating whether CMG technologies improve quality of care measures such as appropriateness of treatment, adherence to guidelines, timeliness of care, safety, and patient-centered care.
7) Does the opportunity support studies of organizational and implementation barriers?
Yes. A major emphasis is understanding barriers and enabling factors that influence uptake and effective use, including clinical workflow, staffing and expertise, specimen handling and interpretation infrastructure, reimbursement and billing practices, leadership support, and care team coordination around results.
8) Are economic evaluations allowed or encouraged?
Yes. The FOA highlights economic evaluation, including direct and indirect costs, budget impact, and cost-effectiveness, reflecting that CMG technologies can be expensive and may require supporting services beyond the test itself.
9) How prominent is health equity in this FOA?
Equity is a specific and prominent priority. The FOA calls for studies of disparities in access and effectiveness of CMG technologies in routine cancer care.
10) What types of disparities can be studied under this announcement?
The FOA allows disparity-focused studies across dimensions such as race and ethnicity, income, geography, insurance status, age, disability, language, and rural versus urban settings.
11) What are examples of equity-related questions this FOA invites?
Examples include gaps in availability of CMG testing, differences in referral patterns, unequal access to specialist interpretation, unequal ability to receive targeted therapies after biomarker identification, and whether test performance or effectiveness differs across populations in routine practice.
12) Does the FOA address how CMG technologies spread across the health system over time?
Yes. It encourages monitoring diffusion over time and across settings, including cross-sectional patterns and time trends such as adoption speed, which sites adopt first, whether adoption spreads into community settings, and whether use aligns with evidence and guidelines.
13) Can projects examine unintended consequences of CMG testing?
Yes. The FOA is interested in downstream effects such as overuse, underuse, and unintended consequences, not only intended benefits.
14) Are studies limited to CMG technologies that are already commercially available?
No. The FOA explicitly welcomes studies of both commercially available CMG tools already in use and experimental tools in later-stage development or moving through regulatory review.
15) Why would the FOA include late-stage experimental tools?
The intent is to allow early evidence about implementation and delivery impact to shape how near-ready technologies are rolled out as they approach routine care.
16) Is interdisciplinary collaboration encouraged?
Yes. The FOA pushes for interdisciplinary collaboration, especially partnerships between health services researchers and clinical and/or translational scientists, to keep studies grounded in clinical realities while applying strong methods from fields like health economics, implementation science, outcomes research, epidemiology, and policy analysis.
17) What is the maximum award amount listed?
The listed award ceiling is $200,000, consistent with the exploratory nature of an R21.
18) Is cost sharing or matching required?
No. The opportunity does not require cost sharing or matching.
19) What agency administers this opportunity?
It is administered by the National Institutes of Health (NIH) and associated with the National Cancer Institute (NCI).
20) What CFDA listing is associated with this grant?
The CFDA listing provided is 93.399 (Cancer Control).
21) Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (including small businesses and other for-profits); and state and county governments. The eligibility description also notes that certain federal agencies, regional organizations, and U.S. territories or possessions may be eligible.
22) Are for-profit organizations allowed to apply?
Yes. For-profit organizations, including small businesses, are included as eligible applicants.
23) Are state or local governments eligible?
Yes. State and county governments are specifically listed as eligible.
24) Is the number of awards known?
No. The anticipated number of awards is not specified and depends on available funds and the number of meritorious applications received.
25) Is there a related funding opportunity for larger projects?
Yes. The FOA notes it runs in parallel with a companion announcement of the same scientific scope using the R01 mechanism (PA 09 004), which may be relevant if a project is better suited to a full-scale study rather than an exploratory award.
26) What are the posted and closing dates shown in the opportunity description?
The opportunity was posted on October 6, 2008. The final closing date shown is January 7, 2012, and it is noted as archived as of February 7, 2012.
27) What is the overall intent of the FOA?
The intent is to generate practical, actionable evidence about how CMG technologies influence cancer care delivery across diverse real-world environments, including academic medical centers, community practices and health systems, and policy and payer contexts.
Browse more opportunities from the same category: Education Health
Next opportunity: Health Services Research on the Prevention and Treatment of Drug and Alcohol Abuse (R21)
Previous opportunity: Understanding the Effects of Emerging Cellular, Molecular, and Genomic Technologies on Cancer Health Care Delivery(R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 005
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 005) also looked into and applied for these:
| Funding Opportunity |
|---|
| Health Services Research on the Prevention and Treatment of Drug and Alcohol Abuse (R21) Apply for PA 08 264 Funding Number: PA 08 264 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Health Services Research on the Prevention and Treatment of Drug and Alcohol Abuse (R03) Apply for PA 08 265 Funding Number: PA 08 265 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis (R21) Apply for PA 08 267 Funding Number: PA 08 267 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Interactions between Physical Activity and Drug Abuse (R01) Apply for RFA DA 09 013 Funding Number: RFA DA 09 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Interactions between Physical Activity and Drug Abuse (R03) Apply for RFA DA 09 014 Funding Number: RFA DA 09 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Basic and Preclinical Research on Complementary and Alternative Medicine (CAM) (R01) Apply for PA 09 010 Funding Number: PA 09 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Mouse Gene Development Initiative (R01) Apply for RFA DA 09 015 Funding Number: RFA DA 09 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medical Management of Older Patients with HIV/AIDS (R01) Apply for PA 09 017 Funding Number: PA 09 017 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R01) Apply for PA 09 020 Funding Number: PA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| International Research Collaboration on Drug Abuse and Addiction Research (R21) Apply for PA 09 021 Funding Number: PA 09 021 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| International Research Collaboration on Drug Abuse and Addiction Research (R03) Apply for PA 09 022 Funding Number: PA 09 022 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Central Nervous System Intersections of Drug Addiction, Chronic Pain and Analgesia (R21) Apply for RFA DA 09 018 Funding Number: RFA DA 09 018 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Secondary Data Analyses for Substance Abuse Research (R21/R33) Apply for RFA DA 09 020 Funding Number: RFA DA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Brain Imaging Studies of Negative Reinforcement in Humans (R01) Apply for RFA DA 09 008 Funding Number: RFA DA 09 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Brain Imaging Studies of Negative Reinforcement in Humans (R21) Apply for RFA DA 09 009 Funding Number: RFA DA 09 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Instrument Development for Biomedical Applications (R21) Apply for RFA RR 09 001 Funding Number: RFA RR 09 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Erythropoiesis Stimulating Agents and Tumor Progression (R01) Apply for PA 09 023 Funding Number: PA 09 023 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Erythropoiesis Stimulating Agents and Tumor Progression (R21) Apply for PA 09 024 Funding Number: PA 09 024 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| National Cancer Institute Program Project (P01) Applications Apply for PAR 09 025 Funding Number: PAR 09 025 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment (U01) Apply for PAR 09 026 Funding Number: PAR 09 026 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 005", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.